WO2010126014A1 - 新規溶媒和物結晶 - Google Patents
新規溶媒和物結晶 Download PDFInfo
- Publication number
- WO2010126014A1 WO2010126014A1 PCT/JP2010/057404 JP2010057404W WO2010126014A1 WO 2010126014 A1 WO2010126014 A1 WO 2010126014A1 JP 2010057404 W JP2010057404 W JP 2010057404W WO 2010126014 A1 WO2010126014 A1 WO 2010126014A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acetone
- crystal
- solvent
- olmesartan medoxomil
- water
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Definitions
- the present invention relates to a novel solvate crystal.
- Olmesartan medoxomil which is an angiotensin II receptor antagonist, is useful as an active ingredient of a medicament for the treatment and prevention of hypertension (for example, Patent Documents 1 to 5 and Non-Patent Documents 1 and 2).
- Olmesartan medoxomil is produced from olmesartan through the following steps, but the final product precursor, trityl olmesartan medoxomil, achieves improved operability and efficient production of high purity final product. Therefore, it has been desired to obtain a new crystal.
- An object of the present invention is to provide a novel triethylolmesartan medoxomil acetone solvate crystal.
- Embodiments of the present invention include the following (1) to (23).
- any one of (13) to (17) The method as described in one. (20) The method according to any one of (13) to (19), wherein seed crystals are inoculated. (21) A method for producing olmesartan medoxomil, comprising a step of removing a trityl group from the crystal according to any one of (1) to (4). (22) The method according to (21), comprising the step according to (5). (23) The method according to (21), comprising the first step and the second step according to (13).
- olmesartan, trityl olmesartan medoxomil, olmesartan medoxomil, olmesartan medoxomil dehydrate, trityl halide, and DMDO halide each represent a compound represented by the structural formula described in the above figure.
- X independently represents a halogen atom such as chloro, bromo or iodo. Tr represents triphenylmethyl.
- DMDO represents a portion excluding X in the structural formula of DMDO halide.
- Trityl olmesartan represents a compound represented by the structural formula shown in the following figure.
- DMDO-Cl DMDO chloride
- Olmesartan 4- (1-hydroxy-1-methylethyl) -2-propyl-1-[[2 '-[1H-tetrazol-5-yl] biphenyl-4-yl] methyl] imidazole-5-carboxylic acid; Trityl olmesartan medoxomil: (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl 4- (1-hydroxy-1-methylethyl) -2-propyl-1-[[2 '-[2 -(Triphenylmethyl) -2H-tetrazol-5-yl] biphenyl-4-yl] methyl] imidazole-5-carboxylate; Olmesartan medoxomil: (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl 4- (1-hydroxy-1-methylethyl) -2-propyl-1-[[2 '-(1H- Tetrazol-5-yl
- the crystal of the present invention refers to a solid whose internal structure is composed of regularly repeated constituent atoms (or a group thereof) in a three-dimensional manner, and is distinguished from an amorphous solid that does not have such a regular internal structure. .
- crystals of the same compound may produce crystals (crystal polymorphs) having a plurality of different internal structures and physicochemical properties depending on the crystallization conditions. Any form may be sufficient and the mixture of two or more crystal polymorphs may be sufficient.
- Examples of the crystal form of the present invention include those showing the pattern of FIG. 1 or FIG. 2 by X-ray crystal diffraction, and those showing the pattern of FIG. 4 or FIG. 5 by thermal analysis, but of trityl olmesartan medoxomil.
- the acetone hydrate crystals are not limited to these.
- novel solvate crystals provided by the present invention are easy to handle and are useful as synthetic intermediates for olmesartan medoxomil.
- FIG. 2 is an X-ray crystal diffraction pattern of the crystal obtained in Example 1.
- FIG. The X-ray crystal diffraction pattern of the crystal obtained in Example 2.
- Olmesartan which is a starting material used in the production method of the present invention, can be easily produced according to the method described in Japanese Patent Publication No. 7-121918 (Patent No. 2082519; US Pat. No. 5,616,599).
- the acetone solvate crystal of trityl olmesartan medoxomil of the present invention can be obtained, for example, through the following steps.
- This step is a step for producing trityl olmesartan by reacting olmesartan with trityl halide in an acetone solvent in the presence of a base.
- trityl halide trityl chloride and trityl bromide are usually used, and trityl chloride is preferred.
- the reaction solvent is usually used in an amount of 5 to 20 (v / w) times that of olmesartan, but is not particularly limited.
- the base used is not particularly limited, but it is preferable to use amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [5,4,0] -7-undecene (DBU), DBU is optimal.
- amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [5,4,0] -7-undecene (DBU), DBU is optimal.
- the reaction temperature is not particularly limited, but is usually 0 ° C. to the boiling point of the solvent, and preferably 20 to 60 ° C.
- trityl olmesartan can be isolated by a method commonly used in the field of synthetic organic chemistry. It is preferable to do.
- This step is a step for producing trityl olmesartan medoxomil by reacting DMDO halide with trityl olmesartan in an acetone solvent in the presence of a base.
- DMDO halide DMDO chloride and DMDO bromide are usually used, and DMDO chloride is preferred.
- the base used is the same as the previous tritylation step, and DBU is preferred.
- the reaction temperature is not particularly limited, but is usually 0 ° C. to the boiling point of the solvent, and preferably 20 to 60 ° C.
- the amount of water contained in the reaction system can be usually adjusted by adding water to the reaction system. Water can be added at once in the tritylation step, but can also be added separately in the tritylation step and the DMDO esterification step.
- the amount of water added to the reaction system is such that the water content contained in the entire reaction system (water content in the reaction system) is an appropriate amount in consideration of the amount of water contained in the starting materials, reaction reagents and solvent. It is preferable to adjust to.
- the water content in the reaction system is the sum of the amount of water contained in the starting material, reaction reagent and reaction solvent, and the ratio (w / w)% of the total water content (weight) to the total weight of the entire reaction mixture [or% (W / w)].
- the amount of water contained in the starting material, the reaction reagent and the reaction solvent can be measured with a Karl Fischer moisture measuring device. Moreover, about the reagent and solvent marketed, it can also calculate using the measured value or specification value described in the package insert by the provider.
- the water content in the reaction system is usually at least 0.3 (w / w)%, preferably at least 0.4 (w / w)%, and most preferably at least 0.5 (w / w)% with respect to the lower limit. It is.
- the upper limit is usually 3 (w / w)% or less, preferably 2 (w / w)% or less, and most preferably 1.5 (w / w)% or less.
- the water content in the reaction system is preferably set to 1.3 (w / w)% or less.
- the water content in the reaction system when considering both the reduction of the impurity content and the reaction efficiency is usually 0.3 to 3.0 (w / w)%, preferably 0.3 to 1.5 (w / w)%. More preferably 0.4 to 1.5 (w / w)%, and most preferably 0.4 to 1.3 (w / w)%.
- the amount of water added to the reaction system can be more simply adjusted as a ratio (w / w)% of the starting material to olmesartan (weight).
- Olmusartan as the starting material is usually used with a water content of 0.3 to 0.5 (w / w)%.
- a DBU having a water content of about 0.5% is usually used.
- Triphenylmethyl chloride (TPC) and DMDO chloride usually contain little water.
- TPC Triphenylmethyl chloride
- acetone is usually used as the solvent, one containing about 0.2% water is usually used.
- Acetone is usually used in an amount 5 to 20 (v / w) times that of olmesartan.
- the amount of water to be added is usually 1.0 (w / w)% or more, preferably 2.0 (w / w)% or more with respect to olmesartan as the lower limit. Most preferably, it is 4.0 (w / w)% or more.
- the amount of water added to the reaction system may be small.
- the upper limit is usually 28 (w / w)% or less, preferably 18 (w / w)% or less, and most preferably 13 (w / w)% or less. Considering both the reduction of the impurity content and the reaction efficiency, it is preferably 10 (w / w)% or less.
- the amount of water added to the reaction system is usually 1.0 to 28 (w / w)%, preferably 1.0 to 13 (w / w)%, more preferably 2.0 to 13 (w / w) based on olmesartan. w / w)%, and most preferably 2.0 to 10 (w / w)%.
- Step of precipitating crystals By cooling the reaction product (reaction solution) obtained in the above step, an acetone solvate crystal of trityl olmesartan medoxomil can be precipitated.
- Acetone hydrate crystals can be precipitated by concentrating or cooling the reaction solution. It can also be precipitated by adding an appropriate amount of water to the reaction solution.
- the water content in the acetone solvent at the time of crystal precipitation is usually 20% (w / w) or less, preferably 10% (w / w) or less, more preferably 5% (w / w) or less. And most preferably 2% (w / w) or less.
- the cooling temperature is preferably 0 to 25 ° C, more preferably 15 to 25 ° C.
- the cooling time is usually 10 minutes or longer, preferably 30 minutes or longer. It is also possible to cool for 6 hours or more.
- Crystal precipitation can start spontaneously in the reaction vessel, but can also be initiated or promoted by applying mechanical stimuli such as seed crystal inoculation, ultrasonic stimulation, or rubbing the surface of the reactor.
- mechanical stimuli such as seed crystal inoculation, ultrasonic stimulation, or rubbing the surface of the reactor.
- seed crystals are preferably inoculated.
- the acetone solvate crystal of trityl olmesartan medoxomil of the present invention can be produced by the following method independently of the production method through the above steps.
- the acetone solvate crystal of trityl olmesartan medoxomil is prepared by dissolving trityl olmesartan medoxomil or a salt thereof prepared by an existing method in an acetone-containing solvent, adjusting the pH, concentrating the solution, mixing the poor solvent, and adding a seed crystal. It can also be produced by conducting the above, etc., and conducting and precipitating the acetone solvate of trityl olmesartan medoxomil into a supersaturated state.
- the acetone-containing solvent is preferably acetone which may contain water. Water can also be added after trityl olmesartan medoxomil is dissolved in acetone.
- the amount of water contained in acetone is not particularly limited as long as it does not prevent precipitation of acetone hydrate crystals, but is usually 20% (w / w) or less, preferably 10% (w / w) or less. It is preferably 5% (w / w) or less, more preferably 2% (w / w) or less.
- Crystal precipitation can start spontaneously in the reaction vessel, but can also be initiated or promoted by applying mechanical stimuli such as seed crystal inoculation, ultrasonic stimulation, or rubbing the surface of the reactor.
- mechanical stimuli such as seed crystal inoculation, ultrasonic stimulation, or rubbing the surface of the reactor.
- the amount of water contained in acetone exceeds 5% (w / w), it is preferable to inoculate seed crystals.
- operations such as pH adjustment, concentration, and cooling may be performed as necessary.
- acetone hydrate crystals can be precipitated by dissolving trityl olmesartan medoxomil in acetone, adding an appropriate amount of water to adjust the water content, and concentrating or cooling the solution.
- acetone solvate crystals can be precipitated by dissolving trityl olmesartan medoxomil in acetone and concentrating the solution or cooling the solution.
- acetone solvate crystals can be precipitated by dissolving trityl olmesartan medoxomil in acetone containing 20% (w / w) or less of water and concentrating the solution or cooling the solution.
- the precipitated crystals can be isolated by, for example, filtration, centrifugation, or gradient method.
- the isolated crystals can be washed with a suitable solvent as necessary.
- a solvent such as water, ethanol, isopropanol, acetone, ethyl acetate, toluene, acetonitrile, methyl acetate or ether can be used, preferably water or water-containing acetone.
- the isolated crystal can be dried usually at a temperature of 10 to 100 ° C., preferably at a temperature of 30 to 50 ° C. until the weight becomes almost constant. If necessary, the crystals can be dried in the presence of a desiccant such as silica gel or calcium chloride, or under reduced pressure.
- a desiccant such as silica gel or calcium chloride
- the dried crystals are usually absorbed at a temperature of 10 to 30 ° C. at a relative humidity of 20% to 90%, preferably at a temperature of 20 to 30 ° C. and a relative humidity of 50% to 80% until the weight is almost constant. Also good.
- the acetone solvate crystal of trityl olmesartan medoxomil of the present invention shows the same pattern as that of FIG. 1 or 2 in X-ray diffraction and FIG. 4 or 5 in thermal analysis (DSC).
- equivalent pattern means a pattern having no significant difference in behavior of main peaks.
- the acetone solvate crystal of trityl olmesartan medoxomil of the present invention contains 1 mol of acetone per 1 mol of trityl olmesartan medoxomil in its dry product.
- the acetone solvate crystal of trityl olmesartan medoxomil of the present invention can be led to olmesartan medoxomil through a detritylation step (step of removing a trityl group). That is, the method for producing olmesartan medoxomil of the present invention includes a step of obtaining olmesartan medoxomil by subjecting the acetone solvate crystal of trityl olmesartan medoxomil obtained in the above step to a detritylation step.
- a feature of the present invention resides in the use of a novel trityl olmesartan medoxomil acetone solvate crystal as a starting material for the detritylation step.
- Examples of the detritylation step include, but are not limited to, the methods described in Patent Document 1, Patent Document 2, Non-Patent Document 1, and Non-Patent Document 2.
- acetone solvate crystal of trityl olmesartan medoxomil of the present invention as a synthetic intermediate, high-purity olmesartan medoxomil with a reduced content of impurities or related substances can be produced.
- impurities or related substances whose content is reduced include olmesartan and olmesartan medoxomil dehydrate.
- the dosage may vary depending on various conditions such as the patient's symptoms, age, weight and the like.
- the dose varies depending on symptoms, age, etc.
- the lower limit per day is 0.001 mg / kg (preferably 0.01 mg / kg)
- the upper limit is 10 mg / kg (preferably 1 mg / kg). Yes, it can be administered 1 to 6 times daily depending on symptoms.
- a tablet containing a dose selected from 5 mg, 10 mg, 20 mg and 40 mg is orally administered once a day. To do.
- the medicament containing high-purity olmesartan medoxomil obtained in the present invention is, for example, hypertension or a disease derived from hypertension (more specifically, hypertension, heart disease [angina, myocardial infarction, arrhythmia, heart failure). Or cardiac hypertrophy], kidney disease [diabetic nephropathy, glomerulonephritis or nephrosclerosis] or cerebrovascular disease [cerebral infarction or cerebral hemorrhage]).
- Example 1 (1) Tritylation and DMDO esterification reaction 4- (1-hydroxy-1-methylethyl) -2-propyl-1-[[2 '-[1H-tetrazol-5-yl] biphenyl-4-yl] methyl ]
- Imidazole-5-carboxylic acid (30 g), acetone (210 mL), 1,8-diazabicyclo [5,4,0] -7-undecene [DBU] (25.5 g) and triphenylmethyl chloride [TPC] (23.79 g )
- Water 0.6 mL was added, and the mixture was washed with acetone (30 mL) and stirred at 48 to 52 ° C. for 2 hours.
- DBU 1,8-diazabicyclo [5,4,0] -7-undecene
- TPC triphenylmethyl chloride
- the precipitated crystals were collected by filtration, washed with acetone water (3360 L), and (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl 4- (1-hydroxy-1-methylethyl)- 2-propyl-1-[[2 '-[2- (triphenylmethyl) -2H-tetrazol-5-yl] biphenyl-4-yl] methyl] imidazole-5-carboxylate crude crystal acetone hydrate crystal wet product (1360kg) was obtained.
- Imidazole-5-carboxylic acid 700 kg
- acetone 5300 L
- 1,8-diazabicyclo [5,4,0] -7-undecene 614 L
- triphenylmethyl chloride [TPC] 570 kg
- Mix rinse with acetone (140 L), add water (14 L), stir at 30-45 ° C. for 1 hour, then at 48-54 ° C. for 2 hours.
- the precipitated crystals were collected by filtration, washed with acetone water (3420L), and (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl 4- (1-hydroxy-1-methylethyl)- 2-propyl-1-[[2 '-[2- (triphenylmethyl) -2H-tetrazol-5-yl] biphenyl-4-yl] methyl] imidazole-5-carboxylate crude crystal wet product (1460 kg) I got it.
- Example 3 X-ray crystal diffraction of acetone hydrate crystal
- the dry crystal obtained in Example 1 and the wet product of the crystal obtained in Example 2 and Reference Example were subjected to about 15 at 60 ° C under vacuum. Powder X-ray crystal diffraction was measured for dry crystals obtained by drying for a period of time.
- FIG. 1 shows the X-ray crystal diffraction pattern of the crystal obtained in Example 1.
- the X-ray crystal diffraction pattern of the crystal obtained in the reference example is shown in FIG.
- Example 4 Thermal analysis of acetone solvate crystals (DSC) The dry crystals obtained in Example 1 and the wet crystals of the crystals obtained in Example 2 and Reference Example were dried at 60 ° C. under vacuum for about 15 hours. It used for analysis (DSC).
- FIG. 4 shows the thermal analysis (DSC) pattern of the crystal obtained in Example 1.
- Fig. 6 shows the thermal analysis (DSC) pattern of the crystal obtained in the reference example.
- Example 5 Acetone content of acetone hydrate crystals
- the dried crystals obtained in Example 1 and the wet products of crystals obtained in Example 2 and Reference Example were dried at 60 ° C for about 15 hours under vacuum. About the dry crystal
- Test conditions Detector Hydrogen ionization detector
- Column Polyethylene glycol for gas chromatography is coated with a thickness of 1 ⁇ m on the inner surface of a fluorinated silica tube with an inner diameter of 0.53 mm and a length of 30 m.
- Injection port temperature A constant temperature around 200 ° C.
- Detector temperature A constant temperature around 200 ° C.
- Carrier gas Helium Flow rate: Adjust so that the retention time of acetone is about 2.5 minutes.
- the acetone content of the crystals obtained in Example 1 and Example 2 was 6.8%. Since trityl olmesartan medoxomil has a molecular weight of 800.91 and acetone has a molecular weight of 58.08, and the latter 1 mol corresponds to 6.76%, the crystals obtained in Examples 1 and 2 contain 1 mol of acetone per 1 mol of trityl olmesartan medoxomil. Was suggested to be included.
Abstract
Description
(1)トリチルオルメサルタンメドキソミルのアセトン和物結晶。
(2)粉末X線結晶回折で図1又は図2と同等のパターンを示す、(1)記載の結晶。
(3)結晶の熱分析で図4又は図5と同等のパターンを示す、(1)又は(2)記載の結晶。
(4)トリチルオルメサルタンメドキソミル1モル当たりアセトン1モルを含有することを特徴とする、(1)乃至(3)のいずれか一つに記載の結晶。
(5)トリチルオルメサルタンメドキソミルのアセトン含有溶液からトリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させる工程を含んでなる、(1)乃至(4)のいずれか一つに記載の結晶の製造方法。
(6)アセトン含有溶液の溶媒が、水を含んでいてもよいアセトンである、(5)記載の方法。
(7)アセトン含有溶液の溶媒が20%(w/w)以下の水を含むアセトンである、(5)記載の方法。
(8)アセトン含有溶液の溶媒が10%(w/w)以下の水を含むアセトンである、(5)記載の方法。
(9)アセトン含有溶液の溶媒が5%(w/w)以下の水を含むアセトンである、(5)記載の方法。
(10)アセトン含有溶液の溶媒が2%(w/w)以下の水を含むアセトンである、(5)記載の方法。
(11)アセトン含有溶液の溶媒がアセトンである、(5)記載の方法。
(12)種結晶を接種することを特徴とする、(5)乃至(11)のいずれか一つに記載の方法。
(13)下記の工程を含んでなる、(1)乃至(4)のいずれか一つに記載の結晶の製造方法:
[第1工程]水を含んでいてもよいアセトン溶媒中でオルメサルタンをトリチル化およびDMDOエステル化する工程;
[第2工程][第1工程]で得られた反応物からトリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させる工程。
(14)結晶析出時のアセトン溶媒中の水分含量が20%(w/w)以下である、(13)記載の方法。
(15)結晶析出時のアセトン溶媒中の水分含量が10%(w/w)以下である、(13)記載の方法。
(16)結晶析出時のアセトン溶媒中の水分含量が5%(w/w)以下である、(13)記載の方法。
(17)結晶析出時のアセトン溶媒中の水分含量が2%(w/w)以下である、(13)記載の方法。
(18)[第1工程]で得られた反応物を0乃至25℃に冷却することによりトリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させることを特徴とする、(13)乃至(17)のいずれか一つに記載の方法。
(19)[第1工程]で得られた反応物を15乃至25℃に冷却することによりトリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させることを特徴とする、(13)乃至(17)のいずれか一つに記載の方法。
(20)種結晶を接種することを特徴とする、(13)乃至(19)のいずれか一つに記載の方法。
(21)(1)乃至(4)のいずれか一つに記載の結晶からトリチル基を除去する工程を含んでなる、オルメサルタンメドキソミルの製造方法。
(22)(5)記載の工程を含んでなる、(21)記載の方法。
(23)(13)記載の第1工程及び第2工程を含んでなる、(21)記載の方法。
オルメサルタン:4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2’-[1H-テトラゾール-5-イル]ビフェニル-4-イル]メチル]イミダゾール-5-カルボン酸;
トリチルオルメサルタンメドキソミル:(5-メチル-2-オキソ-1,3-ジオキソレン-4-イル)メチル 4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2’-[2-(トリフェニルメチル)-2H-テトラゾール-5-イル]ビフェニル-4-イル]メチル]イミダゾール-5-カルボキシレート;
オルメサルタンメドキソミル:(5-メチル-2-オキソ-1,3-ジオキソレン-4-イル)メチル 4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2'-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル]イミダゾール-5-カルボキシレート;
DMDOクロリド(DMDO-Cl):4-クロロメチル-5-メチル-1,3-ジオキソール-2-オン。
本工程は、オルメサルタンにアセトン溶媒中、塩基の存在下にトリチルハライドを反応させてトリチルオルメサルタンを製造する工程である。
本工程は、トリチルオルメサルタンにアセトン溶媒中、塩基の存在下にDMDOハライドを反応させてトリチルオルメサルタンメドキソミルを製造する工程である。
上記の工程で得られた反応物(反応液)を冷却することにより、トリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させることができる。
アセトン和物の結晶は、反応溶液を濃縮または冷却することによって析出させることができる。また、反応液に適当量の水を加えることによっても析出させることができる。 結晶析出時のアセトン溶媒中の水分含量は、通常20%(w/w)以下であり、好適には10%(w/w)以下であり、更に好適には5%(w/w)以下であり、最も好適には2%(w/w)以下である。
(1)トリチル化およびDMDOエステル化反応
4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2’-[1H-テトラゾール-5-イル]ビフェニル-4-イル]メチル]イミダゾール-5-カルボン酸(30g)、アセトン(210mL)、1,8-ジアザビシクロ[5,4,0]-7-ウンデセン[DBU](25.5g)及びトリフェニルメチルクロリド[TPC](23.79g)を混合し、水(0.6mL)を加え、アセトン(30mL)で洗いこみ、48~52℃で2時間撹拌した。その後、水(0.9mL)を加え、4-クロロメチル-5-メチル-1,3-ジオキソール-2-オン[DMDO-Cl](18.5g)を注加し、48~52℃で5時間撹拌した。
(2)トリチルオルメサルタンメドキソミル粗結晶(アセトン和物晶)取得
反応液を20℃に冷却、晶析後、15~25℃で40分間撹拌し、水(96mL)を25minかけて滴下後、0~5℃に冷却し、30分間撹拌した。析出した結晶をろ取し、アセトン水(150mL)で洗浄し、(5-メチル-2-オキソ-1,3-ジオキソレン-4-イル)メチル 4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2’-[2-(トリフェニルメチル)-2H-テトラゾール-5-イル]ビフェニル-4-イル]メチル]イミダゾール-5-カルボキシレート粗結晶湿品(57.83g)を取得した。その後、真空下60℃で約15時間乾燥し、乾品(57.50g)のアセトン和物晶を取得した。
(1)トリチル化およびDMDOエステル化反応
4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2’-[1H-テトラゾール-5-イル]ビフェニル-4-イル]メチル]イミダゾール-5-カルボン酸(700kg)、アセトン(4630L)、1,8-ジアザビシクロ[5,4,0]-7-ウンデセン[DBU](610L)及びトリフェニルメチルクロリド[TPC](570kg)を混合し、水(14L)を加え、アセトン(800L)で洗いこみ、48~52℃で2時間撹拌した。その後、水(20L)を加え、4-クロロメチル-5-メチル-1,3-ジオキソール-2-オン[DMDO-Cl](315L)を注加し、48~52℃で5時間撹拌した。
(2)トリチルオルメサルタンメドキソミル粗結晶(アセトン和物晶)取得
反応液を15~25℃で一夜撹拌晶析後、30℃で水(2170L)を加え、0~5℃に冷却し、30分間撹拌した。析出した結晶をろ取し、アセトン水(3360L)で洗浄し、(5-メチル-2-オキソ-1,3-ジオキソレン-4-イル)メチル 4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2’-[2-(トリフェニルメチル)-2H-テトラゾール-5-イル]ビフェニル-4-イル]メチル]イミダゾール-5-カルボキシレート粗結晶アセトン和物晶 湿品(1360kg)を取得した。
(1)トリチル化およびDMDOエステル化反応
4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2’-[1H-テトラゾール-5-イル]ビフェニル-4-イル]メチル]イミダゾール-5-カルボン酸(700kg)、アセトン(5300L)、1,8-ジアザビシクロ[5,4,0]-7-ウンデセン[DBU](614L)及びトリフェニルメチルクロリド[TPC](570kg)を混合し、アセトン(140L)で洗いこみ、水(14L)を加え、30~45℃で1時間撹拌し、その後、48~54℃で2時間撹拌した。その後、10~20℃で水(20L)を加え、4-クロロメチル-5-メチル-1,3-ジオキソール-2-オン[DMDO-Cl](316L)を注加し、28~32℃で3時間撹拌し、その後、48~52℃で3.5時間撹拌した。
(2)トリチルオルメサルタンメドキソミル粗結晶取得
反応液を28~32℃で一夜撹拌後、25℃で水(2240L)を加え、15~25℃で撹拌晶析後、0~5℃に冷却し、30分間撹拌した。析出した結晶をろ取し、アセトン水(3420L)で洗浄し、(5-メチル-2-オキソ-1,3-ジオキソレン-4-イル)メチル 4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[[2’-[2-(トリフェニルメチル)-2H-テトラゾール-5-イル]ビフェニル-4-イル]メチル]イミダゾール-5-カルボキシレート粗結晶湿品(1460kg)を取得した。
実施例1で得られた乾品の結晶、並びに、実施例2及び参考例で得られた結晶の湿品を真空下60℃で約15時間乾燥して得られた乾品の結晶について、粉末X線結晶回折を測定した。
実施例1で得られた乾品の結晶、並びに、実施例2及び参考例で得られた結晶の湿品を真空下60℃で約15時間乾燥して得られた乾品の結晶を、熱分析(DSC)に供した。
実施例1で得られた乾品の結晶、並びに、実施例2及び参考例で得られた結晶の湿品を真空下60℃で約15時間乾燥して得られた乾品の結晶について、下記の条件でアセトン含量を測定した。
検出器:水素イオン化検出器
カラム:内径 0.53mm、長さ 30mのフーズドシリカ管の内面にガスクロマトグラフ用ポリエチレングリコールを厚さ1μmで被覆する。
流量:アセトンの保持時間が約2.5分になるように調整する。
ヘッドスペース試料導入装置の操作条件
バイアル内平衡温度:80℃付近の一定温度
バイアル内平衡時間:30分間
注入ライン温度:90℃付近の一定温度
キャリヤーガス:ヘリウム
試料注入量:1mL
Claims (23)
- トリチルオルメサルタンメドキソミルのアセトン和物結晶。
- 粉末X線結晶回折で図1又は図2と同等のパターンを示す、請求項1記載の結晶。
- 結晶の熱分析で図4又は図5と同等のパターンを示す、請求項1又は2記載の結晶。
- トリチルオルメサルタンメドキソミル1モル当たりアセトン1モルを含有することを特徴とする、請求項1乃至3のいずれか一つに記載の結晶。
- トリチルオルメサルタンメドキソミルのアセトン含有溶液からトリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させる工程を含んでなる、請求項1乃至4のいずれか一つに記載の結晶の製造方法。
- アセトン含有溶液の溶媒が、水を含んでいてもよいアセトンである、請求項5記載の方法。
- アセトン含有溶液の溶媒が20%(w/w)以下の水を含むアセトンである、請求項5記載の方法。
- アセトン含有溶液の溶媒が10%(w/w)以下の水を含むアセトンである、請求項5記載の方法。
- アセトン含有溶液の溶媒が5%(w/w)以下の水を含むアセトンである、請求項5記載の方法。
- アセトン含有溶液の溶媒が2%(w/w)以下の水を含むアセトンである、請求項5記載の方法。
- アセトン含有溶液の溶媒がアセトンである、請求項5記載の方法。
- 種結晶を接種することを特徴とする、請求項5乃至11のいずれか一つに記載の方法。
- 下記の工程を含んでなる、請求項1乃至4のいずれか一つに記載の結晶の製造方法:
[第1工程]水を含んでいてもよいアセトン溶媒中でオルメサルタンをトリチル化およびDMDOエステル化する工程;
[第2工程][第1工程]で得られた反応物からトリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させる工程。 - 結晶析出時のアセトン溶媒中の水分含量が20%(w/w)以下である、請求項13記載の方法。
- 結晶析出時のアセトン溶媒中の水分含量が10%(w/w)以下である、請求項13記載の方法。
- 結晶析出時のアセトン溶媒中の水分含量が5%(w/w)以下である、請求項13記載の方法。
- 結晶析出時のアセトン溶媒中の水分含量が2%(w/w)以下である、請求項13記載の方法。
- [第1工程]で得られた反応物を0乃至25℃に冷却することによりトリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させることを特徴とする、請求項13乃至17のいずれか一つに記載の方法。
- [第1工程]で得られた反応物を15乃至25℃に冷却することによりトリチルオルメサルタンメドキソミルのアセトン和物結晶を析出させることを特徴とする、請求項13乃至17のいずれか一つに記載の方法。
- 種結晶を接種することを特徴とする、請求項13乃至19のいずれか一つに記載の方法。
- 請求項1乃至4のいずれか一つに記載の結晶からトリチル基を除去する工程を含んでなる、オルメサルタンメドキソミルの製造方法。
- 請求項5記載の工程を含んでなる、請求項21記載の方法。
- 請求項13記載の第1工程及び第2工程を含んでなる、請求項21記載の方法。
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080018900.9A CN102414201B (zh) | 2009-04-28 | 2010-04-27 | 溶剂化物晶体 |
MX2011011540A MX2011011540A (es) | 2009-04-28 | 2010-04-27 | Cristales de solvato novedosos. |
CA2760031A CA2760031C (en) | 2009-04-28 | 2010-04-27 | Acetone solvate crystals of trityl olmesartan medoxomil |
EP10769712.0A EP2426127B1 (en) | 2009-04-28 | 2010-04-27 | Novel solvate crystals |
NZ596326A NZ596326A (en) | 2009-04-28 | 2010-04-27 | Novel solvate crystals |
ES10769712T ES2753874T3 (es) | 2009-04-28 | 2010-04-27 | Cristales de solvato novedosos |
US13/266,967 US8859600B2 (en) | 2009-04-28 | 2010-04-27 | Acetone solvate crystals of trityl olmesartan medoxomil |
SG2011077146A SG175296A1 (en) | 2009-04-28 | 2010-04-27 | Novel solvate crystals |
AU2010242635A AU2010242635A1 (en) | 2009-04-28 | 2010-04-27 | Novel solvate crystals |
BRPI1013336A BRPI1013336B1 (pt) | 2009-04-28 | 2010-04-27 | cristais solvatos de acetona, métodos para produção dos referidos cristais e método para produção de olmesartana medoxomila |
RU2011148101/04A RU2563631C2 (ru) | 2009-04-28 | 2010-04-27 | Новые кристаллы сольватов |
JP2011511396A JP5697593B2 (ja) | 2009-04-28 | 2010-04-27 | 新規溶媒和物結晶 |
ZA2011/07813A ZA201107813B (en) | 2009-04-28 | 2011-10-25 | Novel solvate crystals |
IL215965A IL215965A0 (en) | 2009-04-28 | 2011-10-26 | Solvate crystals and methods of producing the same |
US14/513,984 US20160102079A1 (en) | 2009-04-28 | 2014-10-14 | Acetone solvate crystals of trityl omesartan medoxomil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009109160 | 2009-04-28 | ||
JP2009-109160 | 2009-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010126014A1 true WO2010126014A1 (ja) | 2010-11-04 |
Family
ID=43032159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/057404 WO2010126014A1 (ja) | 2009-04-28 | 2010-04-27 | 新規溶媒和物結晶 |
Country Status (19)
Country | Link |
---|---|
US (2) | US8859600B2 (ja) |
EP (1) | EP2426127B1 (ja) |
JP (2) | JP5697593B2 (ja) |
KR (1) | KR20120006513A (ja) |
CN (1) | CN102414201B (ja) |
AU (1) | AU2010242635A1 (ja) |
BR (1) | BRPI1013336B1 (ja) |
CA (1) | CA2760031C (ja) |
CO (1) | CO6470817A2 (ja) |
ES (1) | ES2753874T3 (ja) |
IL (1) | IL215965A0 (ja) |
MX (1) | MX2011011540A (ja) |
MY (1) | MY158090A (ja) |
NZ (1) | NZ596326A (ja) |
RU (1) | RU2563631C2 (ja) |
SG (2) | SG10201501131SA (ja) |
TW (1) | TWI464162B (ja) |
WO (1) | WO2010126014A1 (ja) |
ZA (1) | ZA201107813B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011021224A2 (en) * | 2009-08-19 | 2011-02-24 | Msn Laboratories Limited | Process for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214469B (zh) * | 2013-04-29 | 2014-12-10 | 孙威 | 一种奥美沙坦酯化合物及其制备方法 |
CN107474042A (zh) * | 2017-09-07 | 2017-12-15 | 浙江华海致诚药业有限公司 | 一种三苯甲基奥美沙坦酯的晶型h |
CN110082449B (zh) * | 2019-05-24 | 2020-05-19 | 珠海润都制药股份有限公司 | 一种奥美沙坦酯中三苯基氯甲烷的检测方法 |
CN113105439A (zh) * | 2021-04-15 | 2021-07-13 | 迪嘉药业集团有限公司 | 一种小粒度奥美沙坦酯的结晶制备方法 |
CN116217628B (zh) * | 2023-05-08 | 2023-07-14 | 华东理工常熟研究院有限公司 | 奥沙利铂Pt(IV)配合物的共晶及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0282519A (ja) | 1988-09-19 | 1990-03-23 | Sanyo Electric Co Ltd | 固相エピタキシャル成長方法 |
JPH07121918B2 (ja) | 1991-02-21 | 1995-12-25 | 三共株式会社 | ビフェニルメチルイミダゾール誘導体 |
US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
WO2006029056A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Preparation of olmesartan medoxomil |
WO2006029057A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Purification of olmesartan medoxomil |
WO2006073519A1 (en) | 2005-01-03 | 2006-07-13 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
WO2007148344A2 (en) * | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Process for the preparation of olmesartan medoxomil |
WO2008043996A2 (en) * | 2006-10-09 | 2008-04-17 | Cipla Limited | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil |
JP2008088172A (ja) * | 2006-09-27 | 2008-04-17 | Dipharma Francis Srl | フェニルテトラゾール化合物の製法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753489A (ja) * | 1993-06-11 | 1995-02-28 | Sankyo Co Ltd | ビフェニルカルボキサミド誘導体の製造法 |
JPH07121918A (ja) | 1993-08-30 | 1995-05-12 | Tdk Corp | 光磁気記録媒体 |
JP3671266B2 (ja) | 1996-03-21 | 2005-07-13 | 東洋化成工業株式会社 | 5−置換テトラゾール類の製造方法 |
JP3521304B2 (ja) | 1996-03-21 | 2004-04-19 | 東洋化成工業株式会社 | 1−(テトラゾリルビフェニルメチル)イミダゾール誘導体の製造方法 |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
IT1295405B1 (it) * | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
JP2004217542A (ja) | 2003-01-10 | 2004-08-05 | Fuji Photo Film Co Ltd | 4,5−ジアルコキシカルボニルイミダゾールの製造方法 |
US20070054948A1 (en) | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
JP2006111586A (ja) | 2004-10-15 | 2006-04-27 | Nippon Petrochemicals Co Ltd | 置換芳香族化合物の酸化方法 |
SI22092A (sl) | 2005-07-29 | 2007-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek za pripravo olmesartan medoksomila |
EA014026B1 (ru) | 2005-07-29 | 2010-08-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Способ получения олмесартан медоксомила |
WO2007047838A2 (en) * | 2005-10-20 | 2007-04-26 | Dr. Reddy's Laboratories Ltd. | Process for preparing olmesartan medoxomil |
CZ299902B6 (cs) | 2005-10-27 | 2008-12-29 | Zentiva, A. S | Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv |
SI2176253T1 (sl) * | 2007-08-08 | 2012-02-29 | Lek Pharmaceuticals D.D. | Postopek priprave ali čiščenja olmesartan medoksomila ali hidrohalidne soli olmesartan medoksomila |
EP2036904A1 (en) * | 2007-08-08 | 2009-03-18 | LEK Pharmaceuticals D.D. | A process for the preparation of olmesartan medoxomil |
WO2009151016A1 (ja) | 2008-06-09 | 2009-12-17 | 第一三共株式会社 | 1-ビフェニルメチルイミダゾール化合物の製造方法 |
EP2334668B1 (en) | 2008-09-05 | 2014-04-02 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for preparing olmesartan medoxomil intermediate |
WO2010126013A1 (ja) * | 2009-04-28 | 2010-11-04 | 第一三共株式会社 | オルメサルタンメドキソミルの製造方法 |
WO2011014611A2 (en) | 2009-07-30 | 2011-02-03 | Dr. Reddy's Laboratories Ltd. | Preparation of olmesartan medoxomil |
US20130190506A1 (en) | 2010-06-28 | 2013-07-25 | Hetero Research Foundation | Process for olmesartan medoxomil |
-
2010
- 2010-04-27 SG SG10201501131SA patent/SG10201501131SA/en unknown
- 2010-04-27 WO PCT/JP2010/057404 patent/WO2010126014A1/ja active Application Filing
- 2010-04-27 AU AU2010242635A patent/AU2010242635A1/en not_active Abandoned
- 2010-04-27 TW TW099113167A patent/TWI464162B/zh active
- 2010-04-27 MY MYPI2011005182A patent/MY158090A/en unknown
- 2010-04-27 MX MX2011011540A patent/MX2011011540A/es active IP Right Grant
- 2010-04-27 KR KR1020117025160A patent/KR20120006513A/ko active Search and Examination
- 2010-04-27 CA CA2760031A patent/CA2760031C/en active Active
- 2010-04-27 NZ NZ596326A patent/NZ596326A/en not_active IP Right Cessation
- 2010-04-27 RU RU2011148101/04A patent/RU2563631C2/ru not_active IP Right Cessation
- 2010-04-27 CN CN201080018900.9A patent/CN102414201B/zh active Active
- 2010-04-27 ES ES10769712T patent/ES2753874T3/es active Active
- 2010-04-27 SG SG2011077146A patent/SG175296A1/en unknown
- 2010-04-27 JP JP2011511396A patent/JP5697593B2/ja active Active
- 2010-04-27 US US13/266,967 patent/US8859600B2/en active Active
- 2010-04-27 EP EP10769712.0A patent/EP2426127B1/en active Active
- 2010-04-27 BR BRPI1013336A patent/BRPI1013336B1/pt active IP Right Grant
-
2011
- 2011-10-25 ZA ZA2011/07813A patent/ZA201107813B/en unknown
- 2011-10-26 IL IL215965A patent/IL215965A0/en unknown
- 2011-11-24 CO CO11161167A patent/CO6470817A2/es not_active Application Discontinuation
-
2014
- 2014-10-14 US US14/513,984 patent/US20160102079A1/en not_active Abandoned
-
2015
- 2015-01-08 JP JP2015002227A patent/JP5944539B2/ja active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0282519A (ja) | 1988-09-19 | 1990-03-23 | Sanyo Electric Co Ltd | 固相エピタキシャル成長方法 |
JPH07121918B2 (ja) | 1991-02-21 | 1995-12-25 | 三共株式会社 | ビフェニルメチルイミダゾール誘導体 |
US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
WO2006029056A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Preparation of olmesartan medoxomil |
WO2006029057A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Purification of olmesartan medoxomil |
JP2007509993A (ja) * | 2004-09-02 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | オルメサルタンメドキソミルの精製法 |
JP2007509992A (ja) * | 2004-09-02 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | オルメサルタンメドキソミルの調製法 |
WO2006073519A1 (en) | 2005-01-03 | 2006-07-13 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
JP2007526342A (ja) * | 2005-01-03 | 2007-09-13 | テバ ファーマシューティカル インダストリーズ リミティド | 低レベルの不純物を有するオルメサルタンメドキソミル |
WO2007148344A2 (en) * | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Process for the preparation of olmesartan medoxomil |
JP2008088172A (ja) * | 2006-09-27 | 2008-04-17 | Dipharma Francis Srl | フェニルテトラゾール化合物の製法 |
WO2008043996A2 (en) * | 2006-10-09 | 2008-04-17 | Cipla Limited | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil |
Non-Patent Citations (4)
Title |
---|
ANNU. REP. SANKYO RES. LAB., vol. 55, 2003, pages 1 - 91 |
J. MED. CHEM., vol. 39, 1996, pages 323 - 338 |
KOIKE, H. ET AL.: "Olmesartan Medoxomil, a Novel Potent Angiotensin II Blocker", ANNU REP SANKYO RES LAB, vol. 55, 2003, pages 1 - 91, XP008147471 * |
See also references of EP2426127A1 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011021224A2 (en) * | 2009-08-19 | 2011-02-24 | Msn Laboratories Limited | Process for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate |
WO2011021224A3 (en) * | 2009-08-19 | 2011-04-28 | Msn Laboratories Limited | Improved process for preparing (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-(tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate |
Also Published As
Publication number | Publication date |
---|---|
BRPI1013336A2 (pt) | 2016-03-29 |
US20120059172A1 (en) | 2012-03-08 |
SG10201501131SA (en) | 2015-04-29 |
CN102414201A (zh) | 2012-04-11 |
AU2010242635A2 (en) | 2014-08-07 |
SG175296A1 (en) | 2011-11-28 |
EP2426127B1 (en) | 2019-09-04 |
RU2563631C2 (ru) | 2015-09-20 |
KR20120006513A (ko) | 2012-01-18 |
JP5697593B2 (ja) | 2015-04-08 |
IL215965A0 (en) | 2012-01-31 |
MY158090A (en) | 2016-08-30 |
TWI464162B (zh) | 2014-12-11 |
AU2010242635A1 (en) | 2011-12-01 |
CA2760031C (en) | 2015-03-10 |
EP2426127A1 (en) | 2012-03-07 |
JP2015071647A (ja) | 2015-04-16 |
ES2753874T3 (es) | 2020-04-14 |
EP2426127A4 (en) | 2012-10-03 |
RU2011148101A (ru) | 2013-06-10 |
BRPI1013336B1 (pt) | 2020-02-04 |
ZA201107813B (en) | 2012-07-25 |
JP5944539B2 (ja) | 2016-07-05 |
NZ596326A (en) | 2014-02-28 |
JPWO2010126014A1 (ja) | 2012-11-01 |
TW201043616A (en) | 2010-12-16 |
MX2011011540A (es) | 2012-04-30 |
US8859600B2 (en) | 2014-10-14 |
US20160102079A1 (en) | 2016-04-14 |
CA2760031A1 (en) | 2010-11-04 |
CN102414201B (zh) | 2015-10-14 |
CO6470817A2 (es) | 2012-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5944539B2 (ja) | 新規溶媒和物結晶およびその製造方法 | |
JP5748954B2 (ja) | チアゾリジンジオン化合物の結晶およびその製造方法 | |
JP6471103B2 (ja) | ヒスタミンh4受容体のベンゾイミダゾール−2−イルピリミジンモジュレータ | |
EP1716139A1 (en) | Olmesartan medoxomil with reduced levels of impurities | |
TWI539948B (zh) | 奧美沙坦酯之製造方法 | |
CN107980038A (zh) | 沙库巴曲钙盐 | |
JP2004520446A5 (ja) | ||
WO2020156150A1 (zh) | 泊马度胺前体药物盐的多晶型物 | |
WO2008027385A2 (en) | Processes for the synthesis of 5-phenyl -1 trityl-1h-tetrazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080018900.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10769712 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011511396 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010769712 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117025160 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2760031 Country of ref document: CA Ref document number: 215965 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/011540 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010242635 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13266967 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 596326 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2362/MUMNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11161167 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2011148101 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2010242635 Country of ref document: AU Date of ref document: 20100427 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1013336 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1013336 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111027 |